Loading clinical trials...
Loading clinical trials...
A Two-Stage, Open-Label Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents
Conditions
Interventions
Pracinostat
Azacitidine
Locations
25
United States
City of Hope
Duarte, California, United States
Scripps Cancer Center-Mercy
San Diego, California, United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
georgia cancer Center
Augusta, Georgia, United States
Pontchartrain cancer Center
Covington, Louisiana, United States
RCCA MD LLC (The Center for Cancer and Blood Disorders)
Bethesda, Maryland, United States
Start Date
June 1, 2017
Primary Completion Date
December 1, 2020
Completion Date
December 1, 2020
Last Updated
March 2, 2022
NCT05636514
NCT07270978
NCT05292664
NCT06499285
NCT04953910
NCT04953897
Lead Sponsor
Helsinn Healthcare SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions